A 38-year-old man is brought to the emergency department due to a severe nosebleed that ha… — USMLE Step 2 CK

A $38$ -year-old man is brought to the emergency department due to a severe nosebleed that has not stopped for $2$ hours, along with bleeding gums and profound fatigue over the past week. His temperature is $37.8^\circ\text{C}$ ( $100.0^\circ\text{F}$ ), blood pressure is $110/70$ mm Hg, and heart rate is $112$ /min. Physical examination reveals diffuse petechiae across his chest and large ecchymoses on his extremities. Laboratory studies show:

Complete Blood Count	Value
Hemoglobin	$8.2$ g/dL
Leukocyte count	$2,100/\text{mm}^3$
Platelet count	$18,000/\text{mm}^3$

Coagulation Profile	Value
Prothrombin time (PT)	$22$ seconds
Activated partial thromboplastin time (aPTT)	$55$ seconds
Fibrinogen	$75$ mg/dL
D-dimer	$>10,000$ ng/mL

A peripheral blood smear reveals pancytopenia and several large, atypical promyelocytes containing multiple needle-like intracytoplasmic inclusions.

Arrange the following steps in the most appropriate chronological order for the optimal management of this patient's condition.

1Empirical administration of all-trans retinoic acid (ATRA)
2Bone marrow aspiration and biopsy
3Molecular confirmation of the PML::RARA fusion gene
4Addition of arsenic trioxide (ATO) to the treatment regimen

Answer

The correct sequence is: 1) Empirical administration of all-trans retinoic acid (ATRA), 2) Bone marrow aspiration and biopsy, 3) Molecular confirmation of the PML::RARA fusion gene, 4) Addition of arsenic trioxide (ATO) to the treatment regimen.

Acute promyelocytic leukemia (APL) is a medical emergency that presents with pancytopenia and severe coagulopathy (DIC), driven by the release of procoagulants from leukemic promyelocytes. The first and most critical step is the empirical administration of all-trans retinoic acid (ATRA). ATRA induces differentiation of the malignant promyelocytes into mature neutrophils, which rapidly halts the coagulopathy and prevents fatal bleeding. Because of the high risk of early mortality from hemorrhage, ATRA must be given as soon as APL is suspected based on peripheral smear morphology (e.g., atypical promyelocytes with Auer rods), without waiting for definitive diagnostic tests. After ATRA is initiated and supportive care (e.g., cryoprecipitate, platelets) is provided, a bone marrow aspiration and biopsy is performed. The obtained marrow sample is then used for molecular confirmation via FISH or PCR to identify the pathognomonic t(15;17) translocation (PML::RARA fusion gene). Once the diagnosis is definitively confirmed and the patient's risk profile is established, arsenic trioxide (ATO) and/or chemotherapy is added to ATRA to complete the definitive induction treatment regimen.

Step-by-Step Solution

Recognize the clinical presentation of Acute Promyelocytic Leukemia (APL).

The patient has pancytopenia, bleeding, DIC (low fibrinogen, elevated PT/aPTT/D-dimer), and atypical promyelocytes with Auer rods (needle-like inclusions).

Identifying APL is critical because it is a hematologic emergency requiring immediate specific intervention.

Determine the immediate next step in management.

Empirical initiation of ATRA is required as the very first step.

ATRA promotes differentiation of the leukemic promyelocytes, rapidly reversing the severe coagulopathy and preventing fatal hemorrhage. It must not be delayed for confirmatory testing.

Identify the proper sequence of diagnostic confirmation.

Bone marrow biopsy is performed to obtain the necessary sample, followed by molecular testing (FISH/PCR) on that sample.

Definitive diagnosis requires identifying the t(15;17) translocation, but the tissue must first be safely collected via biopsy.

Determine the definitive treatment step.

Add ATO (and sometimes anthracyclines, depending on risk stratification) to complete the induction regimen.

Once the diagnosis is genetically confirmed and risk is stratified, standard definitive induction therapy is implemented.

Key Concept

In patients with suspected acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) must be initiated immediately to prevent fatal hemorrhage from disseminated intravascular coagulation (DIC), prior to obtaining a bone marrow biopsy and awaiting molecular confirmation.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic